Dr. Stetler-Stevenson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Nci Nih
10 Center Dr, Room 3s235
Bethesda, MD 20892Phone+1 301-480-8076Fax+1 301-480-8089
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematopathology, 1988 - 1992
McGaw Medical Center of Northwestern UniversityResidency, Pathology-Anatomic and Clinical, 1985 - 1987- Northwestern University The Feinberg School of MedicineClass of 1984
Certifications & Licensure
MD State Medical License 1987 - 2025- American Board of Pathology Anatomic Pathology
Publications & Presentations
PubMed
- 207 citationsPhase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell MalignanciesRobert J. Kreitman, David R. Squires, Maryalice Stetler-Stevenson, P. Noel, David J. FitzGerald
Journal of Clinical Oncology. 2005-09-20 - 662 citationsThe lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemiaYair Herishanu, Patricia Pérez-Galán, Delong Liu, Angelique Biancotto, Stefania Pittaluga
Blood. 2011-01-13 - 20 citationsCD2 is expressed by a subpopulation of normal B cells and is frequently present in mature B-cell neoplasms.Douglas W. Kingma, Paula D. Imus, Xiu Y. Xie, Gregory A. Jasper, Lynn Sorbara
Cytometry. 2002-10-15
Abstracts/Posters
- Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia VariantMaryalice Stetler-Stevenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions ...Maryalice Stetler-Stevenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIVMaryalice Stetler-Stevenson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term D...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Minimal Disease, Maximum BenefitAugust 12th, 2024
High Remission Rate from Anti-CD22 CAR T-cell Therapy in Pediatric ALLDecember 5th, 2016
Grant Support
- Flow Cytometric Evaluation Of BiomarkersNational Cancer Institute2010–2011
- Flow Cytometric Detection Of Malignant Cells In Body FluidsNational Cancer Institute2010–2011
- Flow Cytometric Analysis Of Benign And Malignant TumorsNational Cancer Institute2010–2011
- Flow Cytometric Analysis Of Benign And Malignant TumorsDivision Of Clinical Sciences - Nci2009
- Flow Cytometric Evaluation Of BiomarkersDivision Of Basic Sciences - Nci2009
- Flow Cytometric Detection Of Malignant Cells In Body FluidsDivision Of Basic Sciences - Nci2009
- Flow Cytometric Evaluation Of BiomarkersNational Cancer Institute2008
- Flow Cytometric Analysis Of Benign And Malignant TumorsNational Cancer Institute2007–2008
- THR Role Of TIMP1 In B Cell Differentiation And SurvivalDivision Of Clinical Sciences - Nci2004–2006
- Flow Cytometric Analysis Of Benign And Malignant TumorsDivision Of Clinical Sciences - Nci1996–2006
- Role Of TIMP1 In B Cell Differentiation And SurvivalDivision Of Clinical Sciences - Nci2003
- TIMP-1 Expression By Normal/Neoplastic LymphocytesDivision Of Clinical Sciences - Nci2001
- TIMP-1 Expression By Normal Lymphocytes &In Lymphoid NEDivision Of Clinical Sciences - Nci2000
- Flow Cytometric Analysis Of Benign &Malignant TumorsDivision Of Clinical Sciences - Nci2000
- TIMP 1 Expression By Normal Lymphocytes And In Lymphoid NeoplasmsDivision Of Clinical Sciences - Nci1997–1998
- Phase II Evaluation Of Topotecan In Melanoma An Renal CelllasmsDivision Of Clinical Sciences - Nci1996
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
